Bedrijfsoverzicht
Nyxoah SA is a medical technology enterprise dedicated to the development and commercialization of solutions designed to treat obstructive sleep apnea (OSA). The company focuses on delivering patient-centric, minimally invasive therapies, with its primary offering being the Genio system, which utilizes hypoglossal neurostimulation to address moderate to severe cases of the condition. Operating within the Healthcare sector specifically in the Medical Instruments & Supplies industry, Nyxoah provides specialized medical devices that aim to improve sleep quality and respiratory health through technological innovation. With a market capitalization of $124.87M and an annual revenue of $10.02M, the company represents a small-cap entity in a specialized niche market. The relatively modest market cap and revenue figures indicate that Nyxoah is an early-stage or growth-oriented company where valuation is driven more by future pipeline potential than by established earnings power, reflecting its position as a focused player in a high-value but competitive medical device landscape.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $10.02M alongside a net income of $-90,085,000 and an EBITDA of $-82,354,000, highlighting a significant disparity between top-line growth and bottom-line profitability. The substantial gap between the $10.02M revenue and the negative net income of nearly $90M reveals a highly aggressive cost structure where operating expenses and research and development costs far exceed current earnings generation. Free cash flow stands at $-43,225,376, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating liquidity from its business model. Despite these cash outflows, Nyxoah maintains a cash balance of $48.00M against total debt of $42.08M, suggesting a balance sheet that is currently leveraged but possesses sufficient liquid assets to cover its immediate obligations. The debt-to-equity ratio of 85.64 further underscores the company's reliance on equity financing or its current stage of capitalization where debt is a significant component of its capital structure. Liquidity is maintained with a current ratio of 1.25, which indicates that the company holds enough current assets to cover its short-term liabilities, though with a narrow margin of safety given the negative cash flow. Return on Equity is recorded at -111.0% and Return on Assets at -37.7%, metrics that reveal that management effectiveness in generating shareholder value and asset utilization is currently negative due to the company's investment phase and lack of profitability.
Waarderingsbeoordeling
Valuation metrics for Nyxoah present a complex picture typical of pre-profitable medical device companies, with a trailing P/E ratio listed as N/A due to the lack of positive earnings and a forward P/E of -1.90, which implies that analysts are pricing in future earnings recovery rather than current performance. The price-to-book ratio stands at 2.14, indicating that the market values the company at more than double its book value, suggesting a premium assigned to the company's intangible assets, intellectual property, and future growth prospects despite current losses. Alternative valuation measures such as the price-to-sales ratio of 12.46 and an EV/EBITDA of -1.44 suggest that investors are focusing heavily on revenue generation and market share acquisition rather than traditional earnings-based multiples. The stock's price range over the last year spans from a 52-week low of $2.76 to a high of $8.64, providing a volatility band within which the current trading price fluctuates based on market sentiment regarding the company's clinical data and regulatory milestones. The beta of 0.87 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to large-cap peers, although its high forward P/E and low profitability introduce specific company risks that can cause sharp price movements independent of the broader index.
Growth & Income
Nyxoah SA has demonstrated exceptional top-line expansion with revenue growth of 346.9% year-over-year, while earnings growth is listed as N/A due to the company's ongoing unprofitability. The absence of earnings growth data relative to revenue growth implies that the company is prioritizing rapid market penetration and product adoption over immediate profitability, a common strategy in the medical device sector during the commercialization phase. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, reflecting a capital allocation strategy where all available cash is reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment approach is necessary given the negative free cash flow and the need to sustain operations while the Genio system gains traction in the market. Overall, the company's growth and income profile is characterized by high revenue velocity and zero current income distribution, positioning Nyxoah as a pure growth vehicle that offers no current yield but relies entirely on future profitability to sustain operations and return value to investors.